

Mumbai, 16th October 2024

Wockhardt files fast-acting Insulin Aspart injection (ASPARAPID™) with DCGI; strengthens commitment to diabetes management

Wockhardt, a global pharmaceutical and biotechnology major, announces the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally.

Diabetes remains a critical health issue, affecting more than 77 million people in India and over 537 million people worldwide and expected to be over 643 million by 2030. The prevalence of diabetes is rising sharply, driven by lifestyle changes, aging population, and urbanization.

Wockhardt's Aspart insulin injection (ASPARAPID™) is an indigenously developed product, underscoring the company's end-to-end capabilities in research & development, clinical studies, scale up and manufacturing of biosimilars products. By leveraging integrated infrastructure and expertise, Wockhardt has completed all stages of ASPARAPID™ development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPID™ will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over INR 260 Cr. with only 2 players and is expected to grow significantly in the coming years.

“We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically,” said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. “Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes.”

Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition.

PRESS RELEASE



WOCKHARDT | **LIFE WINS**

Wockhardt Limited

Registered Office:

D-4, MIDC, Chikalthana

Chhatrapati Sambhajnagar

431006, India

Tel.: +91-22-2653 4444

CIN: L24230MH1999PLC120720

www.wockhardt.com

About Wockhardt's Diabetes Biosimilars

Wockhardt is committed to providing high-quality and affordable biotech products and was the first Asian company after innovator to launch Recombinant Human Insulin and first company after innovator to launch long acting Insulin Analog Glargine. Wockhardt has state-of-the-art integrated infrastructure from R&D, clinical studies to manufacturing of biosimilars and manufactures all recombinant biopharmaceutical drug substances at its four facilities in India handling different expression systems of E. coli, mammalian cells and yeast. It has three fully equipped drug product facilities, two in India and one at UK, handling various dosage forms: cartridges, vials, pre-filled syringes, pen assembly. Wockhardt is one of the only diabetes biosimilars company to have designed and developed its own disposable and re-usable pens with global patents.

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company headquartered in Mumbai, India. Employing around ~2600 people and 27 nationalities, it has a presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Around 78% of its global revenues is coming from international businesses.